Cytotoxic T cells (CTLs) and natural killer cells play a major role in the immune response to Epstein-Barr virus (EBV) infection. In X-linked lymphoproliferative (XLP) disease, a severe immunodeficiency, immunodysregulatory phenomena are observed following EBV infection suggesting that defects exist in these effector populations. The gene defective in XLP is SAP (SLAM-associated protein), an adaptor protein that mediates signals through SLAM and other immunoglobulin superfamily receptors including 2B4. We generated EBV specific 
Introduction
X-linked lymphoproliferative disease (XLP), or Duncan's disease, is an inherited syndrome characterized by immune-dysregulatory phenomena typically following Epstein-Barr virus (EBV) infection and which leads to severe infectious mononucleosis, acquired hypogammaglobulinemia and/or malignant lymphoma. 1 The defective gene in XLP has been identified as src homology 2 domain protein 1A (SH2D1A), 2 also known as signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) gene. 3 SAP is thought to be involved in the co-ordination of the immune response to EBV or other viral infections. SAP is expressed in natural killer (NK), CD4+ and CD8+ T cells [3] [4] [5] but not in monocytes 6 and primary B cells, although expression in certain B cell lines has been documented. 7 The ligand for SAP was initially defined as SLAM (CD150), a member of the immunoglobulin superfamily and a co-stimulatory molecule found on the surface of T and B lymphocytes and dendritic cells. 8 SLAM is a self-ligand and has a number of diverse functions including T/B lymphocyte co-stimulation, 9 regulation of T cell cytotoxicity 10 and induction of interferon-(IFN-) in Th1 clones. 8 The binding of SAP to specific cytoplasmic tyrosine motifs of SLAM serves to block the recruitment of the protein tyrosine phosphatase SHP-2 to SLAM and thus may prevent phosphatase activity at the cell membrane. SAP also binds to other Ig superfamily members, including 2B4, which is expressed on NK cells and cytotoxic T cells and is a molecule implicated in the regulation of T and NK cell cytotoxicity, 11, 12 Ly-9, which is found on mature murine T cells, B cells and thymocytes, and CD84, which is expressed at low levels on human T cells. 13 Recent molecular models of SAP function suggest that at least in murine cells SAP binds to the SH3 domain of the phosphotyrosine kinase FynT [14] [15] [16] and is necessary for recruitment of this molecule to SLAM. However, despite an improved understanding of the structure of SAP and its interactions with these signaling molecules and pathways, the cellular pathogenesis of XLP remains unclear.
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In the majority of cases of XLP, EBV plays a critical role as a trigger of pathological phenotypes. EBV is a human -1 herpesvirus that infects most people early in life resulting in infectious mononucleosis (IM), a systemic illness characterized by the proliferation of EBVinfected B lymphocytes and unusually strong NK, CD4+ and CD8+ virus-specific cytotoxic T lymphocyte (CTL) responses. In XLP it has been suggested that the inability of the immune system to control EBV-infected B lymphocyte proliferation may be due to defects of T helper (Th) cells, cytotoxic T cells and/or NK cells. Studies of NK cells from XLP patients show failure of 2B4 mediated cytotoxic killing of CD48 expressing target cells and EBVimmortalized lymphoblastoid B cell lines (LCLs). 12, 17, 18 This defect is thought to arise from the delivery of an inhibitory signal through the 2B4/CD48 interaction, since disruption of this association restores normal cytolytic function.
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Studies on specific T cell immunity to EBV in XLP are contradictory. EBV specific memory T cell activity as measured by inhibition of autologous LCLs outgrowth (regression assay) was defective in the majority of XLP patients studied by Harada et al. (1982) 19 but other studies claim normal EBV specific HLA-restricted cytotoxic activity 20 , although no specific blocking experiments were undertaken. The production of IFN-has been studied by a number of groups but is again inconclusive. Although Yasuda et al. (1991) 21 demonstrated that T cells from XLP patients exhibit a significant decrease in IFN-production, in another study mononuclear cells from one XLP patient during acute EBV infection showed elevated levels of serum IFN-compared to EBV seropositive normal individuals. 22, 23 More recently it was shown that Herpesvirus saimiri transformed CD4+ T cells from XLP patients exhibited severe defects in upregulation of IFN-and IL-2 on T-cell receptor and SLAM stimulation and mixed lymphocyte reactions in comparison to controls. 24 In murine SAP 'knockout' models, lymphocyte development is normal but challenge with LCMV or Toxoplasma results in increased T cell activation, proliferation and excessive IFN-production with a bias to a Th1 T cell profile. 5, 25 Together, these human and murine studies suggest that disturbance of the For personal use only. on . by guest www.bloodjournal.org From Th1/Th2 cytokine balance and dysregulation of T lymphocyte cytotoxic function may be crucial to the cellular pathogenesis of the condition but as yet no data has been reported in a clinically relevant model.
To understand the cellular defects in XLP we developed an autologous EBV-LCL/EBV-T cell line model from XLP patients and studied the phenotypic profile and functionality of effector T cells. We show that in response to specific stimuli, the IFN-response in XLP patients is defective and that, although T cells from XLP patients are capable of generating EBV specific T cell lines (EBV-T cell lines), they lack cytotoxic activity against autologous LCLs. Finally, using a retrovirus gene delivery system encoding human SAP cDNA, we demonstrate reconstitution of cytokine secretion and cytotoxic function in patient EBV-T cell lines, thereby confirming SAP dependent cellular defects in XLP.
Materials and Methods

Generation of SAP expressing retroviral vector
Human SAP(SH2D1A) cDNA (OMIM no: AL023657) cloned into pGEM-T (Promega, Madison, USA) was a gift from Dr. Alison Coffey (The Sanger Center, Cambridge, UK). SAP cDNA was amplified using the primers described below. The forward primer, SAP-F, containing a Sal I restriction site (underlined), was placed upstream of the initiation codon and the reverse primer, SAP-R, downstream at codon 553 but upstream of the polyA+ signal.
Primers:
SAP-F: GCC CAA GAG TCG ACC AGG CCA TGG SAP-R: GTA CAA GGT GTT TTA GTC GAC TTC ATG GGG GCT TTC The 400bp product was digested with Sal I and cloned into pBS (Promega, Madison, WI), sequenced and then subcloned into the retroviral backbone. A murine replication deficient oncoretroviral vector containing the U3 modified 3` LTR from SFFV, 5`LTR from PCMV (PCC4 cell passaged murine sarcoma virus), 26 and PBS (Primer binding site) 27 was used for enhanced haematopoietic cell tropism and reduced transgene silencing. Human SAP cDNA was cloned upstream of the encephalomyocarditis virus derived internal ribosomal entry sequence (IRES) sequence and red shifted variant of the green fluorescent protein (eGFP).
Vectors containing only eGFP were generated for controls in all experiments. The PG13 packaging cell line (providing the Gibbon ape leukemia virus envelope protein) was used to generate replication defective virus. One clone producing virus at 10 7 transducing units/ml was selected.
Purification of PBMCs from normal and XLP patients
This study was approved by the Institutional research ethics committee and informed consent was obtained from all subjects before taking blood. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density centrifugation from anti-coagulated whole blood derived from three healthy donors (C) and three XLP patients (P1, P2 and P3).
The three patients were all from different kindreds and each had a different mutation in the weeks stimulation to reach maximum transduced cell purity.
LDH Release Cytotoxic Assay
Cytoxicity of EBV-T cell lines was measured using LDH release assays (Promega, Madison, USA). Briefly, autologous LCLs were used as target cells with EBV-T cell lines as effector cells at different effector:target cell ratios. All targets were plated in triplicate. After a 4h incubation supernatants were harvested and the specific cytotoxicity determined using a microplate ELISA reader (Dynatech Labs Inc., Chantilly, VA). The percentage of specific lysis was calculated as 100% × (experimental release [-] spontaneous release)/(maximum release
[-] spontaneous release). Maximum release was obtained by adding 100 µL of 5% Triton X-100 to the 100 µL medium containing target cells. Spontaneous release was consistently below 15% of maximum release in all assays.
ELISPOT assay
The ELISPOT assay was performed as described 29 was then compared against the control response for each experiment and analysed for statistical significance using a one tail unpaired T-test assuming, unequal variance between the two study groups. Significant differences are indicated by asterisks (no asterisk, no statistical significance; *, p<0.05; **, p<0.01; ***, p<0.001).
SAP Immunoblotting
Cell lysates were prepared from SAP reconstituted and non-reconstituted EBV-T cell lines from patients and healthy donors, according to previous protocols. 
Flow cytometric analysis and FACS
Flow cytometry of EBV-T cell lines was performed using an EPICS XL flow cytometer (Beckman Coulter, High Wycombe, UK) and antibodies for CD3, CD4, CD8, CD16, CD25, CD27, CD28, CD45RA, CD45RO, CD56, CD69, CD95 (Fas), CDw150 (SLAM), CD244
(2B4), TCR , TCR (all from BD Pharmingen, San Diego, CA).
Gene-modified EBV-T cell lines were purified using an EPICS Altra fluorescence activated cell sorter (FACS) (Beckman Coulter, High Wycombe, UK). Cells were stained with phycoerythrin (PE) conjugated CD3 (BD Pharmingen, San Diego, CA) and analyzed for PE-CD3 and eGFP expression. Dual-color positive cells (positive fraction) and single-color CD3 cells (negative fraction) were sorted to high purity (more than 99%). One unsorted fraction was retained. The three cell fractions were subsequently used separately for cytotoxicity assays.
MHC class I blocking of target cells
W6/32 monoclonal antibody (a gift from Dr Bin Gao, ICH, London, UK) was used to block MHC class I antigen presentation on LCLs. Cells were washed twice with PBS and then incubated with W6/32 mAb (1 ug/ml) on ice for 1 h. The cells were then washed and used in cytotoxicity assays.
For
Results
Immunophenotypic characteristics of EBV-T cell lines from XLP patients
The cellular response to EBV infection is mediated predominantly by CD8+ cytotoxic T cells which retain memory and provide lifelong immunity against EBV. The detailed immunophenotype and function of EBV-T cell lines derived from XLP patients has not previously been reported. Using autologous LCLs as stimulators, EBV-T cell lines from two normal individuals (CTLC1 and CTLC2) and two XLP patients (CTLP1 and CTLP2) were generated. Detailed cell surface analysis of CD8+ and CD4+ EBV-T cell lines generated from both XLP patients and normal individuals revealed similar surface marker expression profiles (Table 1) . Expression of memory/naive (CD45RO/CD45RA) and activation (CD25 and CD69) markers was similar in cell lines derived from normal and XLP individuals with comparable mean fluorescence intensity (MFI) for the majority of markers studied.
Previous reports have suggested that SLAM is the dominant molecule mediating cytotoxicity in T lymphocytes. However, in this analysis we found very low surface expression of SLAM on EBV-T cell lines from both normal and XLP individuals, while in contrast 2B4 is highly expressed on these cell lines (Figure1, Table 1 ), suggesting that 2B4 rather than SLAM may be more important in mediating cytotoxicity in EBV-T cell lines. (Figure 2A ). Cells were then activated with more specific stimuli. In these specific receptor stimulation experiments we observed significant differences in IFNproduction between controls and patient responses. After stimulation with CD3, CD3/2B4 and 2B4, significantly less IFN-secretion was observed in patient samples compared to controls (Fig 2B and 2C) . One exception to this was P3 (who was EBV seronegative at the time of analysis), who showed an increased IFN-response following CD3 stimulation. His reponses to CD3/2B4 and 2B4 were similar to the other patients. Cells were then stimulated with autologous EBV immortalized LCLs and again the IFN-was decreased in all patients, although in P3 who was EBV seronegative and where no spots were observed, this would be expected due to lack of memory to EBV (Fig 2C) . Cells were also stimulated with CD28, CD3/CD28, SLAM or CD3/SLAM but no differences were observed between control individuals and XLP patients (data not shown).
IFN-production in
EBV-T cell line function in XLP and reconstitution of defects following SAP gene transfer
It has been postulated that the cellular pathogenesis of XLP may reside in abnormal function of EBV-T cell lines and in their inability to control EBV infection. Previous reports, performed before the identification of the SAP gene defect, are inconclusive with certain studies demonstrating that cytokine secretion and cytoxicity are abnormal and others suggesting that both functions are intact. We examined whether introducing expression of the SAP gene into EBV-T cell lines from XLP patients (known to lack SAP expression) could restore these observed functional defects. We transduced EBV-T cell lines from XLP patients P1 and P2 (CTLP1 and CTLP2) with a retroviral vector encoding the SAP cDNA and the reporter eGFP 
Discussion
Following the identification of SAP as the defective gene in XLP, there has been considerable progress in the understanding of the SAP protein structure, its interaction with cell surface molecules and more recently with proximal tyrosine kinases such as Fyn T. 15, 16 However, the cellular pathogenesis of XLP in humans remains poorly understood, especially given the different clinical phenotypes of the disease. Murine models of SAP deficiency suggest a tendency to a dysregulated Th1 responses with T cell activation and increased IFN-production, but it is clear from studies of other immunodeficiencies that abnormalities observed in murine models do not always accurately reflect human disease. 30 It is evident from a number of reports that human NK cell defects are present in this condition, 17, 18, 31 A number of studies have reported cytokine abnormalities in XLP. However, in the majority of studies undertaken, the response to specific cell surface stimuli has not been addressed. In this analysis we stimulated both PBMCs and XLP EBV-T cell lines with specific T cell stimuli and assessed the IFN-response. In both populations, differences were observed in response to CD3, CD3/2B4, 2B4 or autologous LCLs and not in response to PMA, CD28, CD3/CD28, SLAM or CD3/SLAM. The lack of response to CD3/SLAM or SLAM alone would be in keeping with the low levels of SLAM observed in these cell lines.
Following CD3 stimulation alone, P1 and P2, who are EBV experienced, demonstrate significant downregulation of IFN-production. This is in keeping with observations made by Sanzone et al. where EBV experienced XLP patients were analysed. 35 However, P3 (who was EBV-seronegative at the time of analysis) shows an exaggerated IFN-response that is significantly elevated from controls and is similar to the CD3 stimulation T cell responses observed in SAP deficient mice. 5, 25 Importantly stimulation via 2B4 or CD3/2B4 in P3 shows a downregulated response and is similar to P1 and P2. These observations albeit in only one patient, suggest that SAP deficiency in the EBV inexperienced individual augments CD3 stimulation which after EBV infection is downregulated. The role of SAP downstream of CD3 triggering without co-stimulatory input is unclear but these data suggest a regulatory role for SAP which needs further investigation in larger numbers of patients.
In our study, differences in XLP and normal EBV-T cell lines following CD3/2B4 or 2B4 activation suggest that activation through this specific pathway is important in EBV Our studies on human cells from EBV experienced individuals demonstrate a decrease in IFN-production in response to specific stimuli and contrast significantly with murine data. A possible explanation for this discrepancy may be the fact that in murine studies, animals were examined at an early age and only after limited antigenic exposure. It would be interesting to repeat these studies on mice exposed to repeated or chronic antigen stimuli.
This would better mimic the situation in XLP, which was initially described as a 'progressive' immunodeficiency and where repeated immunological insults and more specifically with EBV may result in a gradual deterioration in immune function.
We demonstrate that human EBV-T cell lines from two patients with a molecular diagnosis of XLP and lack of SAP expression show significant defects in direct killing of autologous LCLs.
Previous studies have suggested this using indirect assays such as LCL growth regression.
That this defect occurs via the 2B4/CD48 pathway is supported by the abundance of 2B4
For personal use only. on . by guest www.bloodjournal.org From rather than SLAM expression and also by the demonstration of 2B4/CD48 abnormalities in NK cell cytotoxicity in XLP. 18 The molecular detail of this pathway is unclear but it has been
shown that 2B4 associates with the LAT (linker for activation of T cells) leading to tyrosine phosphorylation of both molecules. Whether this interaction is SAP dependent has yet to be defined. It is also evident that other receptors are involved in mediating cytoxicity in T cells.
NTB -A is a recently identified member of the SLAM family and can bind SAP following phosphorylation of its cytoplasmic tail. by guest
